Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Core Insights - Pharvaris presented significant clinical data on deucrictibant at the 2025 ACAAI Annual Meeting, highlighting its potential impact on patients with bradykinin-mediated diseases [1][2] Long-Term Prophylaxis - The final analysis of the CHAPTER-1 study showed that deucrictibant reduced the mean attack rate from 2.18 attacks/month to 0.12 attacks/month over approximately 34 months, demonstrating a well-tolerated safety profile [3][4] - Clinically meaningful improvements in disease control and health-related quality of life were observed with deucrictibant treatment for up to 34 months [4][5] - Sustained therapeutic exposure was confirmed with the once-daily oral extended-release tablet, showing therapeutic effects lasting over 24 hours [5][6] On-Demand Therapy - Data from the RAPIDe-2 study indicated that approximately 85% of attacks treated with a single dose of deucrictibant achieved symptom resolution within 24 hours, with a median time to complete resolution of 10.6 hours [7][8] - The treatment was well-tolerated, with 97.8% of attacks achieving symptom relief within 12 hours [8][9] - A propensity score-matched analysis showed that deucrictibant-treated attacks had more favorable outcomes compared to standard care across most efficacy endpoints [10] Expansion Beyond HAE - Pharvaris developed a clinically validated kinin biomarker assay to measure bradykinin levels, which may aid in identifying and managing bradykinin-mediated angioedema [11][12] - The assay could potentially identify further applications for deucrictibant as a bradykinin B2 receptor antagonist [12] About Deucrictibant - Deucrictibant is an oral bradykinin B2 receptor antagonist in clinical development for preventing and treating bradykinin-mediated angioedema attacks [13][14] - It has received orphan drug designation from regulatory authorities, indicating its potential significance in treating rare diseases [14][15] About Pharvaris - Pharvaris is focused on developing oral therapies for bradykinin-mediated angioedema, aiming to provide injectable-like efficacy with the convenience of oral administration [15]